A Phase 1b, Multicenter, Open-Label, Safety, Tolerability, and Activity Study of SYNT001 in Subjects With Chronic Pemphigus (Vulgaris or Foliaceus)
Phase of Trial: Phase I/II
Latest Information Update: 02 Dec 2017
At a glance
- Drugs SYNT 001 (Primary)
- Indications Pemphigus vulgaris
- Focus Adverse reactions
- Sponsors Syntimmune
- 01 Nov 2017 According to a Syntimmune media release, topline data from this trial is expected in the first half of 2018.
- 14 Jul 2017 Status changed from not yet recruiting to recruiting.
- 14 Mar 2017 New trial record